drinking with glp-1 shifts alcohol market dynamics | EY Man's Ozempic curveball he noticed

And, based on the data so far, a significantly larger effect size than anything that came before

Known for their growing role in weight management, these medications were originally developed to help people with Type 2 diabetes

JAMA Cardiol (2020) 5(10):118290

(2019) Medium-chain triglyceride diet stimulates less GIP secretion and suppresses body weight and fat mass gain compared with long-chain triglyceride diet

Richard Frank, MD, MHSA, Chief Medical Officer at Vida Health, spoke to Medical News Today about how orforglipron may expand access to GLP-1s: The choice between a pill and an injectable comes down to patient preference and potency. The injectables are clearly more potent but require a weekly injection